GleamWall
中文EN

TARA Protara Therapeutics, Inc.

Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1359931 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-48.3%
TTM EPS YoY-0.0%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-57.4%
ROA-52.1%
ROIC (approx.)-57.3%
Asset turnover—

Leverage & solvency

Liabilities / assets9.9%
Debt / equity0.00x
Current ratio9.01x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.92x
Accruals ratio-4.2%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue————————
R&D expense$16.80M$16.95M$13.56M$13.12M$9.59M$10.77M$9.15M$9.50M
SG&A expense$6.35M$6.37M$6.07M$5.96M$5.17M$5.82M$4.98M$4.81M
Operating income-$23.15M-$23.32M-$19.63M-$19.08M-$14.76M-$16.59M-$14.12M-$14.31M
Net income-$21.69M-$21.67M-$17.78M-$17.31M-$13.26M-$14.96M-$11.91M-$12.77M
EBITDA-$23.08M-$23.25M-$19.54M-$18.99M-$14.67M-$16.49M-$14.04M-$14.23M
EPS (basic)-0.35-0.36-0.31—-0.31-0.35-0.29—
EPS (diluted)-0.35-0.36-0.31—-0.31-0.35-0.29—
Weighted avg. shares (diluted)62.85M61.01M57.54M—42.27M42.27M40.71M—
Banking
Net interest income$1.29M$1.48M——$1.06M$1.22M——
Balance sheet
Cash & equivalents$25.15M$17.08M$14.74M$49.66M$13.30M$32.24M$92.21M$163.54M
Short-term investments$101.90M$125.42M$121.05M$105.90M$120.12M$90.72M$32.90M$7.49M
Current assets$129.67M$146.15M$140.00M$159.50M$135.64M$125.09M$126.53M$172.16M
PP&E, net$1.58M$1.32M$669,000$759,000$828,000$912,000$988,000$1.03M
Total assets$156.54M$176.09M$191.92M$209.47M$144.64M$156.93M$168.56M$181.45M
Current liabilities$14.39M$13.32M$8.92M$10.94M$9.91M$9.76M$7.02M$10.96M
Total liabilities$15.52M$14.78M$10.71M$13.06M$12.35M$12.51M$10.07M$14.32M
Shareholders' equity$141.02M$161.31M$181.21M$196.41M$132.29M$144.42M$158.48M$167.13M
Shares outstanding59.97M59.08M55.06M53.59M38.59M38.58M38.58M35.04M
Cash flow statement
Operating cash flow-$18.44M-$15.39M-$21.34M-$16.95M-$12.45M-$12.25M-$14.71M-$9.31M
Capital expenditure$723,000——$24,000$4,000$22,000$44,000$0
Free cash flow-$19.16M——-$16.97M-$12.46M-$12.27M-$14.76M-$9.31M
Investing cash flow$26.10M$17.75M-$14.72M-$26.91M-$6.51M-$47.72M-$58.35M$22.50M
Financing cash flow$412,000-$26,000$1.14M$80.96M$13,000$8,000$1.73M$97.85M
Depreciation & amortization$71,000$72,000$90,000$93,000$88,000$98,000$83,000$82,000
Stock-based compensation$1.59M$1.38M$1.36M$1.04M$1.05M$903,000$833,000$904,000

Free plan shows the latest 8 periods; Pro shows all 55 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.